key: cord-1025458-zfk5glq0
authors: padovani, a.; Cristillo, V.; tomasoni, d.; gipponi, s.; Pilotto, A.
title: SARS-CoV-2 vaccination predicts COVID-19 progression and outcomes in hospitalized patients
date: 2021-11-26
journal: nan
DOI: 10.1101/2021.11.21.21266633
sha: c5273302ad3f15c9924519e3cd7c85695e8f2204
doc_id: 1025458
cord_uid: zfk5glq0

Background SARS-CoV-2 vaccination might impact on clinical progression of cases with breakthrough COVID-19 disease. Objective to evaluate the impact of SARS-CoV-2 vaccination on disease progression in COVID-19 hospitalized patient Methods and Findings Two-hundred eighty-four consecutive COVID-19 hospitalized patients, including 50 vaccinated cases entered the study. Compared to unvaccinated cases, vaccinated patients were older, exhibited more comorbidities and did not differ for COVID-19 severity at admission. During hospitalisation, unvaccinated patients showed worse disease progression, including higher need of oxygen and higher risk of death compared to vaccinated patients (OR 3.3; 1.05-10.7 95% CI in the whole cohort and OR 54.8; 3.5-852 in the ventilated cases). Discussion These findings argue for an important reduction in severity among vaccine breakthrough infection compared to unvaccinated cases in COVID-19 disease.

Vaccination against SARS-CoV-2 consistently exhibited high efficacy in reducing the incidence of COVID-19 either in trials [1] or in real-world settings [2, 3] . Nevertheless, COVID-19 disease has been reported in patients who underwent SARS-Cov-2 vaccination [4] . A recent study has demonstrated that mRNA vaccination was significantly less likely among hospitalized patients with severe COVID-19 [5] .

In this observational study, we aimed at evaluating the impact of vaccination on disease progression, by controlling for premorbid conditions and severity at admission.

The study included all consecutive patients hospitalized for SARS-CoV-2 infection at the preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. increased in ventilated subjects (OR 62.6; 2.9-1327; p<.008).

These findings are in agreement with epidemiological data claiming for a reduction of raw mortality in vaccinated subjects, independently from the development of the disease [1] [2] [3] [4] [5] . In addition, our study showed that vaccination has a protective effect on clinical course by reducing the progression and lethality, even in the elderly with elevated multimorbidity. In particular, the positive effect on lethality was dramatic among the most severe cases, as the risk of death increased from 

SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Association between mRNA vaccination and COVID-19 hospitalisation and disease severity JAMA 2021